These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26430811)

  • 1. RAS mutations - for better or for worse in multiple myeloma?
    Leich E; Steinbrunn T
    Leuk Lymphoma; 2016; 57(1):8-9. PubMed ID: 26430811
    [No Abstract]   [Full Text] [Related]  

  • 2. A high frequency of N-RAS oncogene mutations in multiple myeloma.
    Tanaka K; Takechi M; Asaoku H; Dohy H; Kamada N
    Int J Hematol; 1992 Oct; 56(2):119-27. PubMed ID: 1421173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenes in multiple myeloma: point mutation of N-ras.
    Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
    Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
    Matozaki S; Nakagawa T; Nakao Y; Fujita T
    Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
    Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and RAS gene mutations in multiple myeloma.
    Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
    Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.
    Ortega MM; Faria RM; Shitara ES; Assis AM; Albuquerque DM; Oliveira JS; Noguti MA; Faria JR; Costa FF; Lima CS
    Leuk Lymphoma; 2006 Feb; 47(2):285-9. PubMed ID: 16321859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
    Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological significance of RAS mutations in multiple myeloma.
    Chng WJ; Gonzalez-Paz N; Price-Troska T; Jacobus S; Rajkumar SV; Oken MM; Kyle RA; Henderson KJ; Van Wier S; Greipp P; Van Ness B; Fonseca R
    Leukemia; 2008 Dec; 22(12):2280-4. PubMed ID: 18528420
    [No Abstract]   [Full Text] [Related]  

  • 11. [Molecular analysis of multiple myeloma cells].
    Yasuga Y; Hirosawa S
    Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
    Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
    Leuk Lymphoma; 2016; 57(1):226-9. PubMed ID: 25947035
    [No Abstract]   [Full Text] [Related]  

  • 13. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.
    Crowder C; Kopantzev E; Williams K; Lengel C; Miki T; Rudikoff S
    Oncogene; 2003 Feb; 22(5):649-59. PubMed ID: 12569357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
    Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
    Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N- and K-ras oncogenes in plasma cell dyscrasias.
    Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
    Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
    Santucci R; Mackley PA; Sebti S; Alsina M
    Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
    Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
    Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autologous peripheral blood stem cell transplantation for double-refractory myeloma with K-RAS and N-RAS mutations].
    Jimbo K; Yokoyama K; Ogawa M; Hirano M; Ochi K; Kobayashi M; Yusa N; Shimizu E; Kawamata T; Yasui H; Ohno N; Yamaguchi R; Imoto S; Furukawa Y; Miyano S; Imai Y; Tojo A
    Rinsho Ketsueki; 2017; 58(12):2380-2385. PubMed ID: 29332870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of multiple myeloma.
    Drach J; Kaufmann H; Urbauer E; Schreiber S; Ackermann J; Huber H
    J Cancer Res Clin Oncol; 2000 Aug; 126(8):441-7. PubMed ID: 10961386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.